HSBC Holdings
TRDA icon

HSBC Holdings’s Entrada Therapeutics TRDA Stock Holding History

HSBC Holdings’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Sell
36,470
-1,667
-4% -$16K ﹤0.01% 2554
2026
Q1 		$472K Buy
38,137
+17,304
+83% +$198K ﹤0.01% 2246
2025
Q4 		$216K Buy
20,833
+194
+0.9% +$1.64K ﹤0.01% 2664
2025
Q3 		$117K Buy
+20,639
New +$121K ﹤0.01% 2578

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

HSBC Holdings's TRDA Position: Q2 2026 in Review

HSBC Holdings reduced its Entrada Therapeutics (TRDA) stake by 4.4% in Q2 2026, selling an estimated $16K and leaving 36,470 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #2554.

HSBC Holdings first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $472K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • HSBC Holdings held 36,470 shares of Entrada Therapeutics worth $278K as of Q2 2026.
  • HSBC Holdings sold 1,667 Entrada Therapeutics shares in Q2 2026, an estimated $16K.
  • Entrada Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2554 holding.
  • HSBC Holdings first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • HSBC Holdings's Entrada Therapeutics position peaked at $472K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.